That would be major but I think they need to have more news on development of the pretest to attract the type of investor they mentioned for percentage of net revenue scenario. I think the UTI as the first focus infection may be for that purpose. They can assign a very verifiable cost to sufferers and insurance providers for that infection. The GBS is more subjective in it’s impact even though the elimination of that infections consequences on newborns plays more to one’s heartstrings, the economic impact is what insurers will seek. I’m interested in seeing both their pretest and N-Assay hit the market for sepsis. That would be of huge consequence, to diagnose sepsis in a day and know precisely what antibiotics to use for a specific bacteria. I know from speaking with Mr. Barnhizer that he’s devoted to shaving percentages off of the 250,000 yearly sepsis deaths through use of their tests. 2020 should be the year people notice.